about
Impact of HIV-1 backbone on neutralization sensitivity: neutralization profiles of heterologous envelope glycoproteins expressed in native subtype C and CRF01_AE backboneIsolation of monoclonal antibodies with predetermined conformational epitope specificityInternational network for comparison of HIV neutralization assays: the NeutNet report IIA phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost.Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models.A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.International network for comparison of HIV neutralization assays: the NeutNet report.Human erythrocytes selectively bind and enrich infectious HIV-1 virions.Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies.Phase I study of safety and immunogenicity of an Escherichia coli-derived recombinant protective antigen (rPA) vaccine to prevent anthrax in adultsPhase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara-HIV-1 vaccine candidateBiologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01_AE, and CRF02_AG, for the development and assessment of candidate vaccines.Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1.Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccinesB cell depletion in HIV-1 subtype A infected Ugandan adults: relationship to CD4 T cell count, viral load and humoral immune responses.Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbitsHuman monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades.The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralizationMultivalent dendrimeric compounds containing carbohydrates expressed on immune cells inhibit infection by primary isolates of HIV-1.High-throughput multiplex HLA genotyping by next-generation sequencing using multi-locus individual taggingSafety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults.Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC.Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.Designing a soluble near full-length HIV-1 gp41 trimer.Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression systemExceptionally potent and broadly cross-reactive, bispecific multivalent HIV-1 inhibitors based on single human CD4 and antibody domains.Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa.Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults.Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites.Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine ResearchInclusion of a CRF01_AE HIV envelope protein boost with a DNA/MVA prime-boost vaccine: Impact on humoral and cellular immunogenicity and viral load reduction after SHIV-E challenge.Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial.Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trialsAssociation of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170).Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.Safety and Immunogenicity of a Randomized Phase 1 Prime-Boost Trial With ALVAC-HIV (vCP205) and Oligomeric Glycoprotein 160 From HIV-1 Strains MN and LAI-2 Adjuvanted in Alum or PolyphosphazeneInfectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees
P50
Q28535477-0C827531-30D5-48F7-B4BE-F2A96394ED8FQ28728170-1FE41CFD-27B3-4119-920D-DAF3DACB4C62Q28730045-27881465-A2EF-4E14-B78B-473995770B8DQ30364914-FC763DE2-2383-43BB-A7A2-0DEA7C10E140Q30369026-3C640446-F365-4405-B05B-9A1DF5425054Q31031447-A3BDACA9-F9C3-4CA5-9A6B-0D5230D9D40CQ33410826-853EDADF-0461-45F8-BEC1-3C460874AB48Q33518534-1B6109BA-D6B7-462D-BB38-59BCE6A50BEBQ33614365-A83DAF5C-0847-4497-8340-3362F79DE5A1Q33747721-46A713F1-BA0F-4667-A651-C86D2A48AACBQ33749950-4356D135-2F25-4EA8-83E8-A74E372EE8FAQ33780524-18B000EA-13CC-44C5-937F-42BE5D7AE6BCQ33895810-18C2592A-13A4-4589-9914-42724167EB4EQ33911935-3CB20CC1-340E-4C34-832B-CFDCB5DD1A09Q34008741-423B65D8-8818-4701-978B-418198F078FAQ34057672-BC4A19A1-4D0D-4957-827F-A3F602A16E07Q34145199-A937480D-B676-4E35-A5AA-9F48854597DDQ34234905-07AC9392-F0BC-4A7D-8860-9BC82F111709Q34253227-538383CA-839D-491E-AF3A-1A9B56026575Q34333656-41025AC7-B829-4220-9F1A-B4B9C9428F7CQ34335632-1BE1820B-5BA8-4422-81F2-C39FDF3C5B48Q34357068-B4485A23-E6E8-4203-9E03-6F3550850CB8Q34412302-FF8D5FD7-1899-4549-9E67-1A7EBCA4FEA2Q34438489-FA9D02E4-22C9-4CA0-9B42-2ABB8DA8440BQ34489464-12BF4036-BE43-42F3-9AA7-0E022E44C089Q34754733-A0CE0A24-9F77-4575-BC4E-E986A30B124FQ35033324-8A3EAFB9-FDDA-4DB7-B6B9-9B23EF6F2D01Q35060140-40A7707F-E732-40D2-B546-CC63299BCFA2Q35129224-22BA4EA1-01F6-41A8-8804-8255D14B75E3Q35140032-C89E270B-E892-4E3A-BEA5-342FB41AABE3Q35415717-E79A1A70-8A21-4804-9541-708D4F714755Q35635418-50287227-0C20-4A11-83CE-98B76AA0C715Q35861256-D31F4723-2122-4A41-9CE0-DEF3187CA84CQ35883032-3BE299B6-D057-489A-8695-144C4DB050A1Q36021144-066E3BE5-2143-4C41-9F7B-FC49D52EB468Q36083337-917AEC0C-515D-465F-BC68-57D0BAD39106Q36421569-9B3046F7-21A8-4E63-9897-52A0BA498772Q36697992-0C0C5135-6FF5-4F67-B8D0-550DB586277AQ36931790-0B98A862-4814-450D-8E53-6BEB1C96597FQ36978671-83BF9EEE-990F-42DE-96F2-F39741E26789
P50
name
Victoria R Polonis
@en
type
label
Victoria R Polonis
@en
prefLabel
Victoria R Polonis
@en